SeekGene Secures Tens of Millions RMB in Pre-A Financing from Delian Capital to Advance Single-Cell Immune Profiling Technologies

On October 28, 2019, SeekGene announced the completion of a tens-of-millions-yuan Pre-A financing round invested by Delian Capital. The funds from this round will be primarily used for the commercial promotion of the company’s single-cell sequencing kits and the research and development of various single-cell detection technologies. It is reported that SeekGene previously received angel investment from ZhenFund in October 2018.

SeekGene (Beijing SeekGene Biotechnology Co., Ltd.), established in 2015, is positioned as a technology-driven biotechnology enterprise specializing in the development and clinical translational applications of single-cell sorting and detection technologies. The SeekGene operations team brings years of experience in scientific research and clinical services, with a focus on applying single-cell sequencing technologies in real-world clinical studies. The company’s independently developed high-throughput single-cell transcriptome sequencing kit delivers world-leading performance while offering flexibility, ease of use, cost-effectiveness, and accuracy, thereby accelerating the clinical translation and application of single-cell sequencing technologies.

In the future, the company will continue to integrate high-throughput single-cell sequencing with adaptive cellular immunotherapy, aiming to monitor the human immune system at higher resolution at both the transcriptomic and proteomic levels, thereby providing new perspectives and solutions for disease screening and drug discovery.

Li Zongwen, Founder and CEO of SeekGene, stated, “Multidimensional single-cell technologies have played a pivotal pioneering role in bridging the gap between basic research and clinical translation, leveraging their unique advantages in disease and drug research. SeekGene will remain dedicated to exploring single-cell technologies, gradually expanding its R&D pipeline, and continuously advancing the application of these technologies in real-world clinical settings.”

Dr. Chen Xinying of Delian Capital stated, “Single-cell technology has elevated our understanding of biological sciences to the single-cell dimension. It has recently become a focal point for the research, clinical, and industrial communities, and represents one of the key niche sectors prioritized by Delian Capital. Single-cell technology can assist pharmaceutical companies in identifying new drug targets and mechanisms of action, and holds the potential to provide more precise methods for clinical diagnosis and monitoring in the future. SeekGene’s single-cell sequencing products combine high performance with rapid, simple workflows and cost advantages, which we believe will meet the needs of a broader base of research users. Furthermore, SeekGene plans to launch more powerful experimental tools in the future to help researchers and pharmaceutical R&D teams deepen their understanding of immunology, while continuously building its proprietary database. The founding team possesses outstanding capabilities in innovative product development and execution, along with many years of experience in the genetic diagnostics industry. We are pleased to support SeekGene’s research and exploration in the field of single-cell technology, and we are confident that the company will continue to achieve breakthroughs in this niche sector, making significant contributions to sustained clinical benefits.”